



Supplemental Fig. S1. (A) Comparison of nonalcoholic fatty liver disease (NAFLD) components between apolipoprotein E ($ApoE$)^{-/-} and $ApoE$ ^{-/-} farnesoid X receptor (FXR)^{-/-} mice. (B) Comparison of NAFLD components in $ApoE$ ^{-/-} FXR ^{-/-} mice fed with Western diet (WD) with or without pioglitazone or fenofibrate treatment. Error bars stand for standard deviation. ^aA significant difference between $ApoE$ ^{-/-} and $ApoE$ ^{-/-} FXR ^{-/-} mice; ^bA significant difference between $ApoE$ ^{-/-} FXR ^{-/-} mice with no treatment and $ApoE$ ^{-/-} FXR ^{-/-} mice treated with fenofibrate